NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Receives Key Patent from European Patent Office
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has been issued a patent by the European Patent Office. The company received notification that the patent was issued covering the company’s flagship technology that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device. This patent offers protection in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The company noted that the newly issued patent “expands on HeartBeam’s granted and pending core patents for remote heart attack detection.” The company is working to increase quality of life for cardiac patients by reducing the fear of chest pain with technology and devices that provide a patient-friendly means of obtaining a 12-lead ECG at any time. “This initial European patent strengthens our intellectual property protection for our HeartBeam AIMIGo technology offering 12-lead ECG capability as we expand our product applications to reach a variety of regions in the global marketplace,” said HeartBeam CEO and Founder Branislav Vajdic, PhD, in the press release. “We continue to enhance our intellectual property to provide protection of our technology in priority global markets.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has been issued a patent by the European Patent Office. The company received notification that the patent was issued covering the company’s flagship technology that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo(TM) credit card-sized device. This patent offers protection in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The company noted that the newly issued patent “expands on HeartBeam’s granted and pending core patents for remote heart attack detection.” The company is working to increase quality of life for cardiac patients by reducing the fear of chest pain with technology and devices that provide a patient-friendly means of obtaining a 12-lead ECG at any time. “This initial European patent strengthens our intellectual property protection for our HeartBeam AIMIGo technology offering 12-lead ECG capability as we expand our product applications to reach a variety of regions in the global marketplace,” said HeartBeam CEO and Founder Branislav Vajdic, PhD, in the press release. “We continue to enhance our intellectual property to provide protection of our technology in priority global markets.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
